These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 1566498)

  • 21. Leflunomide prolongs pulmonary allograft and xenograft survival.
    Yuh DD; Gandy KL; Morris RE; Hoyt G; Gutierrez J; Reitz BA; Robbins RC
    J Heart Lung Transplant; 1995; 14(6 Pt 1):1136-44. PubMed ID: 8719461
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Modulation of effector cell functions in experimental autoimmune encephalomyelitis by leflunomide--mechanisms independent of pyrimidine depletion.
    Korn T; Magnus T; Toyka K; Jung S
    J Leukoc Biol; 2004 Nov; 76(5):950-60. PubMed ID: 15328336
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Complete control of humoral and cell-mediated xenoreactions with the combination of leflunomide and cyclosporine.
    Chong AS; Shen J; Xiao F; Blinder L; Foster P; Sankary H; Williams JW
    Transplant Proc; 1996 Apr; 28(2):684. PubMed ID: 8623344
    [No Abstract]   [Full Text] [Related]  

  • 24. Production of human sperm-immobilizing antibodies in severe combined immunodeficient (SCID) mice reconstituted with human peripheral blood lymphocytes from infertile women.
    Shibahara H; Tsuji Y; Koyama K
    Am J Reprod Immunol; 1996 Jan; 35(1):57-60. PubMed ID: 8789561
    [No Abstract]   [Full Text] [Related]  

  • 25. Administration of tacrolimus (FK506) in hamster-to-rat pancreas xenotransplantation.
    Sakimoto H; Fukuda Y; Sumimoto K; Urushihara T; Ikeda M; Yamanaka K; Okugawa K; Nishihara M; Ito H; Dohi K
    Transplant Proc; 1996 Jun; 28(3):1433-4. PubMed ID: 8658727
    [No Abstract]   [Full Text] [Related]  

  • 26. A novel immunomodulating agent--leflunomide inhibits experimental autoimmune diabetes in mice.
    Stosić-Grujicić S; Dimitrijević M; Bartlett RR
    Transplant Proc; 1996 Dec; 28(6):3072-3. PubMed ID: 8962189
    [No Abstract]   [Full Text] [Related]  

  • 27. FK778, a powerful new immunosuppressant, effectively reduces functional and histologic changes of chronic rejection in rat renal allografts.
    Pan F; Ebbs A; Wynn C; Erickson L; Jang MS; Crews G; Fisniku O; Kobayashi M; Paul LC; Benediktsson H; Jiang AH
    Transplantation; 2003 Apr; 75(8):1110-4. PubMed ID: 12717186
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The immunosuppressant leflunomide inhibits lymphocyte progression through cell cycle by a novel mechanism.
    Cherwinski HM; McCarley D; Schatzman R; Devens B; Ransom JT
    J Pharmacol Exp Ther; 1995 Jan; 272(1):460-8. PubMed ID: 7529314
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Leflunomide in experimental transplantation. Control of rejection and alloantibody production, reversal of acute rejection, and interaction with cyclosporine.
    Williams JW; Xiao F; Foster P; Clardy C; McChesney L; Sankary H; Chong AS
    Transplantation; 1994 Apr; 57(8):1223-31. PubMed ID: 8178350
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Histological and immunological characteristics of, and the effect of immunosuppressive treatment on, xenograft vasculopathy.
    Briffa NP; Shorthouse R; Chan J; Silva H; Billingham M; Brazelton T; Morris RE
    Xenotransplantation; 2004 Mar; 11(2):149-59. PubMed ID: 14962277
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacological profile of A85 4777, a novel antiinflammatory agent with nonclassical immunosuppressive properties.
    Bartlett RR; Schleyerbach R; Schorlemmer KU; Wolf E
    Transplant Proc; 1990 Aug; 22(4):1666-70. PubMed ID: 2389430
    [No Abstract]   [Full Text] [Related]  

  • 32. Effects of leflunomide on immune responses and models of inflammation.
    Bartlett RR; Anagnostopulos H; Zielinski T; Mattar T; Schleyerbach R
    Springer Semin Immunopathol; 1993; 14(4):381-94. PubMed ID: 8322168
    [No Abstract]   [Full Text] [Related]  

  • 33. The different influences of allosensitization and xenosensitization on cellular rejection.
    Fryer JP; Chen S; Johnson EM; Sun LH; Matas AJ
    Transplant Proc; 1996 Apr; 28(2):674. PubMed ID: 8623338
    [No Abstract]   [Full Text] [Related]  

  • 34. Generation of suppressor cells maintains donor-specific tolerance after intrathymic injection of alloantigen.
    Nakafusa Y; Arima T; Goss JA; Flye MW
    Transplant Proc; 1995 Feb; 27(1):128-9. PubMed ID: 7878881
    [No Abstract]   [Full Text] [Related]  

  • 35. Effect of leflunomide, cyclosporine, and splenectomy in two different organ systems of concordant xenotransplantation in rats.
    Salomon S; Steinbrüchel DA; Nielsen B; Lillevang S; Kemp E
    Transplant Proc; 1996 Apr; 28(2):698-9. PubMed ID: 8623352
    [No Abstract]   [Full Text] [Related]  

  • 36. Suppression of hepatic allograft rejection in the rat by mitomycin C-treated donor splenocytes: tissue distribution of donor class I major histocompatibility complex antigen-positive cells in the recipient.
    Goto M; Yamaguchi Y; Hamaguchi H; Hisama N; Miyanari N; Ichiguchi O; Mori K; Shirakusa T; Ogawa M
    Transplant Proc; 1995 Apr; 27(2):1625-7. PubMed ID: 7725428
    [No Abstract]   [Full Text] [Related]  

  • 37. Comparative effects of malononitriloamide analogs of leflunomide on whole blood lymphocyte stimulation in humans, rhesus macaques, cats, dogs, and rats.
    Gregory CR; Silva HT; Patz JD; Morris RE
    Transplant Proc; 1998 Jun; 30(4):1047-8. PubMed ID: 9636423
    [No Abstract]   [Full Text] [Related]  

  • 38. Adoptively transferred lymphocytes from donors treated with cyclosporine reveal less predilection to migrate to allografts.
    Maksymowicz M; Olszewski WL; Szczesny G
    Transplant Proc; 1994 Dec; 26(6):3519. PubMed ID: 7998257
    [No Abstract]   [Full Text] [Related]  

  • 39. A novel mechanism of action of the immunomodulatory drug, leflunomide: augmentation of the immunosuppressive cytokine, TGF-beta 1, and suppression of the immunostimulatory cytokine, IL-2.
    Cao WW; Kao PN; Aoki Y; Xu JC; Shorthouse RA; Morris RE
    Transplant Proc; 1996 Dec; 28(6):3079-80. PubMed ID: 8962191
    [No Abstract]   [Full Text] [Related]  

  • 40. Dihydroorotate dehydrogenase is a target for the biological effects of leflunomide.
    Williamson RA; Yea CM; Robson PA; Curnock AP; Gadher S; Hambleton AB; Woodward K; Bruneau JM; Hambleton P; Spinella-Jaegle S; Morand P; Courtin O; Sautés C; Westwood R; Hercend T; Kuo EA; Ruuth E
    Transplant Proc; 1996 Dec; 28(6):3088-91. PubMed ID: 8962196
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.